The role of granulocyte growth factors in the treatment of non small cell lung cancer

Clinica Terapeutica

Volumn 150, Issue 3, 1999, Pages 231-234

  Gridelli, Gridelli ^a   Barzelloni, M L ^a   Barletta, E ^a   Guida, C ^a   Gatani, T ^a   Fiore, F ^a   Scognamiglio, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Granulocyte growth factors; High dose chemotherapy; NSCLC

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINDESINE;

BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; DRUG MEGADOSE; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; REVIEW; TREATMENT PLANNING;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TAXOIDS; VINBLASTINE;

EID: 0345363278     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. ASCO Ad Hoc Colony-Stimulating Factor Guidelines Expert Panel: American Society of Clinical Oncology recommendation for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471-2508, 1994
2. Update of recommendation for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. By the American Society of Clinical Oncology. J Clin Oncol 14: 1957-1960, 1996
3. 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidlines. By the American Society of Clinical Oncology. J Clin Oncol 15: 3288, 1997
4. Williams SF, Bitran JD, Hoffman PC, et al.: High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non small cell lung cancer. Cancer 63: 238-242, 1989
5. Lazarus HM, Spitzer TR, Creger RJ: Phase I trial of high-dose etoposide, high-dose cisplatin, and reinfusion of autologous bone marrow for lung cancer. Am J Clin Oncol 13: 107-112, 1990
6. Gandara DR, Perez EA, Wold HG, et al.: High dose cisplatin and mtomycin C in advanced non small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol 27: 243-247, 1990
7. Hesketh PJ, Tansan S, Caguioa PB, et al.: Treatment of advanced non small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C. Cancer 71: 717-720, 1993
8. Shin DM, Dhingra HM, Lee JS, et al.: Phase II study of combination therapy with high dose cisplatin, etoposide, and mitomycin in patients with advanced non small cell lung cancer. Am J Clin Oncol 15: 194-199, 1992
9. Gandara DR, Crowley J, Livingston RB, et al.: Evaluation of cisplatin intensity in metastatic non small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873-878, 1993
10. Egurchi K, Kabe J, Kudo S et al. Efficacy of recombination human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non small cell lung cancer. Cancer Chemother Pharmacol 34: 37-43, 1994.
11. Font A, Puerto JM, Moyano A, et al.: A randomized trial comparing cisplatin plus etoposide at maximum tolerated dose (MTD) with/without granulocyte-macrophage colony-stimulating factor (rh-GM-CSF) in advanced non small cell lung cancer (NSCLC). A Spanish Lung Cancer Group Study. Ann Oncol 7: 89, 1996 (suppl. 5) (abstr.)
12. Takada M, Fukuoka M, Ariyoschi Y, et al.: The use of granulocyte colony.stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non small cell lung cancer. Cancer Chemother Pharmacol 31: 182-186, 1992
13. Hiddemann W, Niederle N, von Pawel J, et al.: Treatment of NSCLC with escaleted doses of carboplatin/vindesine followed by G-CSF versus standard dose therapy. Ann Oncol 3: 30, 1992 (suppl. 5) (abstr.)
14. Bonomi P, Kim K, Chang A, et al.: Phase III trial comparing etoposide (E), cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 15: 382, 1996 (abstr.)
15. Belani CP, Aisner J, Hiponia D, Engstrom C: Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non small cell lung cancer. Sem Oncol 22: 7-12, 1995 (suppl. 9) (abstr.)
16. Langer CJ, Lerighton JC, Comis RL, et al.: Paclitaxel and carboplatin in combination in the treatment of advanced non small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860-1870, 1995
17. Masters G, Hoffman P, Samuels B, et al.: Paclitaxel (TAX), ifosfamide (IFX), and vinorelbine (NVB) with G-CSF support in advanced non small cell lung cancer (NSCLC): a phase I-II study. Lung Cancer 18: 21, 1997 (suppl. 1) (abstr.)
18. Androulakis N, Dimopoulos AM, Kourousis C, et al.: First-line treatment of advanced non small cell lung cancer (NSCLC) with docetaxel and cisplatin: a multicentric phase II syudy. Proc Am Soc Clin Oncol 16: 461a, 1997 (abstr.)
19. Kourousis C, Androulakis N, Kakolyris S et al.: First line treatment of non small cell lung carcinoma (NSCLC) with docetaxel and vinorelbine: a phase II study. Ann Oncol 7: 93, 1996 (suppl. 5) (abstr.)
20. Early E, Miller VA, Grant SC, et al.: Phase I/II trial of docetaxel (DTX) and vinorelbine (VNR) with filgrastim (G-CSF) in patients (PTS) with advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16: 467 a, 1997 (abstr.)